Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial)
Open Access
- 31 August 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 18 (1), 1-8
- https://doi.org/10.1186/s13063-017-2118-x
Abstract
Atopic dermatitis (AD) is associated with reduced skin microbial diversity and overgrowth of Staphylococcus (S.) aureus. However, the importance of S. aureus colonisation in the complex pathogenesis remains unclear and studies on the effect of anti-staphylococcal therapy in non-infected AD show contradictory results. Long-term interventions against S. aureus might be needed to restore the microbial balance, but carry the risk of bacterial resistance induction. Staphefekt, an engineered bacteriophage endolysin, specifically kills S. aureus leaving other skin commensals unharmed. Bacterial resistance towards endolysins has not been reported, nor is it expected, which allows us to study its effect as long-term anti-staphylococcal treatment in non-infected AD. This is a multi-centre, placebo-controlled, double-blinded and randomized superiority trial with a parallel group design. A total of 100 participants, aged 18 years or older, diagnosed with moderate to severe AD and using a topical corticosteroid in the weeks before enrolment are included in the study. The study is executed in the Erasmus MC University Medical Centre Rotterdam in collaboration with the Havenziekenhuis Rotterdam. After a 2-week run-in period to standardize the corticosteroid use with triamcinolone acetonide 0.1% cream, participants will be randomized to either treatment with Staphefekt in a cetomacrogol-based cream or a placebo for 12 weeks, followed by an 8-week follow-up period. The primary objective is to assess the difference in the need for corticosteroid co-therapy between the Staphefekt and the placebo group, measuring the number of days per week of corticosteroid cream (triamcinolone) use. Secondary outcomes include the difference in use of corticosteroid cream measured in grams, differences in clinical efficacy, quality of life (QoL), microbial composition (includi23ng S. aureus) between the Staphefekt and the placebo group, and the safety and tolerability. The results of this trial will provide data about the effect of long-term anti-staphylococcal therapy with Staphefekt on corticosteroid use, clinical symptoms and QoL in patients with moderate to severe AD. Additional data about growth characteristics of the skin microbiome, including S. aureus, will give insight into the role of the microbiome as a factor in the pathophysiology of AD. ClinicalTrials.gov, NCT02840955 . Registered on 11 July 2016.Keywords
Funding Information
- Micreos Human Health bv
This publication has 35 references indexed in Scilit:
- Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic DermatitisPediatric Dermatology, 2013
- Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitisGenome Research, 2012
- Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane reviewBritish Journal of Dermatology, 2010
- Quality of life and childhood atopic dermatitis: the misery of living with childhood eczemaInternational Journal Of Clinical Practice, 2006
- Adverse effects of topical glucocorticosteroidsJournal of the American Academy of Dermatology, 2006
- The Patient-Oriented Eczema MeasureArchives of Dermatology, 2004
- Quality of life and disease severity are correlated in children with atopic dermatitisBritish Journal of Dermatology, 2004
- Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 1998
- The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis II. Observer variation of clinical diagnosis and signs of atopic dermatitisBritish Journal of Dermatology, 1994
- The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis..British Journal of Dermatology, 1994